Evernorth records $504.7M in cumulative XRP impairments
Evernorth carried 346.3M XRP at $341.9M as of September 30. Cumulative impairments date back to 2025 and do not represent a sale of the tokens.

Evernorth reported $504.7 million in cumulative XRP impairments through September 30, 2026, in its quarterly SEC filing. The historical cost of 346,284,972 tokens was $846.6 million, compared with a carrying value of $341.9 million. The accounting reduction does not represent a sale of XRP for that amount.
Several periods, rather than one quarter
The company recognized $233.7 million of impairment in 2025 and another $271 million during the first nine months of 2026. The latter figure includes $6.9 million in the third quarter. Treating the entire $504.7 million as a single quarter’s expense or a new cash outflow would misstate the disclosure.
Token quantity and carrying value describe different things. A lower accounting value does not, by itself, demonstrate that the company reduced its reserve. These figures also do not describe the public company’s entire reserve after its business combination: the reporting date preceded that transaction.
Why the accounting matters
Evernorth says its XRP falls outside the scope criteria of the newer ASC 350–60 crypto accounting standard because of its relationship with Ripple. It continues to account for those holdings as indefinite-lived intangible assets, measured at historical cost less accumulated impairment.
That approach differs from fair-value accounting. Comparing the carrying amount directly with a live token quote mixes accounting methods and measurement dates. The impairment charge alone cannot establish how many tokens were sold or how much the company realized in trading losses.
A pre-combination reporting period
The business combination closed on October 9, and CoinLab previously covered the Nasdaq listing. A September reporting date does not mean that the listing remains an upcoming event.
Evernorth reported a $32.9 million net loss for the first nine months, while third-quarter net income was $155.3 million. A noncash change in the fair value of refundable investor advances materially affected those results. Period earnings, XRP impairments and cash movements therefore need to be assessed separately.



Comments